Abexxa Biologics, is a research stage bio-pharmaceutical startup focused on discovering and developing breakthrough antibody-based drugs to its proprietary class of targets designed to revolutionize cancer treatments by providing highly effective targeted therapies. Abexxa research facility is located at biotech innovation hub, LabCentral.
Abexxa Biologics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/abexxa-biologics-inc-” connections=”true” suffix=””]
AbeXXa is looking to identify a new series of selective molecular targets for cancer from the many thousands of proteins found on the interior of a tumor cell.
In 2016, AbeXXa won the Boston Innovation Prize sponsored by Boehringer Ingelheim and has also received funding through the Boehringer Ingelheim Venture Fund.
Also, In Sep 2016, Abexxa Biologics raised $1.25 Mn in seed funding through Equity.